Clinical efficacy of SARS‐CoV‐2 Omicron ‐neutralizing antibodies in immunoglobulin preparations for the treatment of agammaglobulinemia in patients with primary antibody deficiency
Journal of Medical Virology · 2024
DOI: 10.1002/jmv.29738 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Michael Karbiener und 9 weiteren Autor:innen. Beteiligte Einrichtung: Global Pathogen Safety, Takeda Manufacturing Austria AG, Vienna, Austria. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, Agammaglobulinemia, COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceuticals International.
Abstract (Originalsprache)
Immunocompromised individuals are at significantly elevated risk for severe courses of coronavirus disease 2019 (COVID‐19). In addition to vaccination, severe acute respiratory syndrome coronavirus 2 ( SARS‐CoV‐2 ) neutralizing antibodies (nAbs) have been applied throughout the pandemic, with time of treatment onset and potency against the currently prevailing virus variant identified as relevant factors for medical benefit. Using data from the European Society for Immunodeficiencies (ESID) registry, the present study evaluated COVID‐19 cases in three groups of patients with inborn errors of immunity (IEI; 981 agammaglobulinemia patients on immunoglobulin replacement therapy (IGRT); 8960 non‐agammaglobulinemia patients on IGRT; 14 428 patients without IGRT), and the neutralizing capacity of 1100 immunoglobulin lots against SARS‐CoV‐2 (“Wuhan” and Omicron strains), throughout 3 years. From the first (2020/2021) to the second (2021/2022) cold season, i.e., during the virus drift to the more contagious Omicron variants, an increase in case numbers was recorded that was comparable (~2‐ to 3‐fold) for all three study groups. During the same period, immunoglobulin lots showed a profound nAb increase against the archetypal SARS‐CoV‐2 strain, yet only low levels of Omicron nAbs. Notably, shortly before the third (2022/2023) cold season, Omicron ‐neutralizing capacity of released immunoglobulin lots had plateaued at high levels. From the second to the third cold season, COVID‐19 cases dropped markedly. While a ~6‐fold case reduction was recorded for the groups of non‐agammaglobulinemia patients on IGRT and IEI patients not receiving IGRT, the decline was ~30‐fold for the group of agammaglobulinemia patients on IGRT. These findings suggest a substantial COVID‐19‐protective effect of IGRT, at least for distinct groups of antibody‐deficient patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Global Pathogen Safety, Takeda Manufacturing Austria AG, Vienna, Austria.
- Institute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
- Centre for Biobanking FREEZE, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
- Department of Pediatrics, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
- Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
- Adult Immunodeficiency Unit, Infectious Diseases, Inflammation Center, University of Helsinki and HUS Helsinki University Hospital, Helsinki, Finland.
ORCID-Profile: Michael Karbiener, Gerhard Kindle, Isabelle Meyts, Mikko R J Seppänen, Fabio Candotti, Marta Kamieniak, Thomas R Kreil, Markus G Seidel
Förderung
- Takeda Pharmaceuticals International
Zitieren
APA
Karbiener, M., Kindle, G., Meyts, I., Seppänen, M. R. J., Candotti, F., Kamieniak, M., Ilk, R., Kreil, T. R., Seidel, M. G., & ESID‐COVID Consortium (2024). Clinical efficacy of SARS‐CoV‐2 Omicron ‐neutralizing antibodies in immunoglobulin preparations for the treatment of agammaglobulinemia in patients with primary antibody deficiency. Journal of Medical Virology. https://doi.org/10.1002/jmv.29738
Vancouver
Karbiener M, Kindle G, Meyts I, Seppänen MRJ, Candotti F, Kamieniak M, et al. Clinical efficacy of SARS‐CoV‐2 Omicron ‐neutralizing antibodies in immunoglobulin preparations for the treatment of agammaglobulinemia in patients with primary antibody deficiency. Journal of Medical Virology. 2024. doi:10.1002/jmv.29738
BibTeX
@article{Karbiener2024,
author = {Karbiener, Michael and Kindle, Gerhard and Meyts, Isabelle and Seppänen, Mikko R J and Candotti, Fabio and Kamieniak, Marta and Ilk, Reinhard and Kreil, Thomas R and Seidel, Markus G and ESID‐COVID Consortium, ESID‐COVID Consortium},
title = {Clinical efficacy of SARS‐CoV‐2 Omicron ‐neutralizing antibodies in immunoglobulin preparations for the treatment of agammaglobulinemia in patients with primary antibody deficiency},
journal = {Journal of Medical Virology},
year = {2024},
doi = {10.1002/jmv.29738}
}
EUVIMED